Volume 2, Issue 3 (Multidisciplinary Cancer Investigation 2018)                   Multidiscip Cancer Investig 2018, 2(3): 30-35 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Jalaeikhoo H, Zokaasadi M, Rajaeinejad M, Keyhani M, Sharifzadeh M. Study of Multiple Myeloma Occurrence in Patients With 5%-10% Bone Marrow Plasma Cells: A Case Series Regarding Revised IMWG Diagnostic Criteria. Multidiscip Cancer Investig 2018; 2 (3) :30-35
URL: http://mcijournal.com/article-1-196-en.html
1- AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran.
2- Hematology and Oncology Research Center, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran. Address: Keshavarz Blvd., Imam Khomeini Hospital Complex, Vali-Asr hospital, Tehran, Iran.
3- AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran. , morteza.sharifzade@gmail.com
Abstract:   (4258 Views)
Introduction: Utilizing lower limit of bone marrow plasma cells (BMPCs) is the main existing criterion for diagnosis of multiple myeloma (MM). According to the revised international myeloma working group (IMWG) diagnostic criteria, the value of 10% is agreed among experts as the cutoff level for diagnosis. Symptomatic patients with BMPC above this value are identified as definite cases of MM. However, there are MM patients who have BMPC of less than 10%. Considering abovementioned cutoff could delay the diagnosis which in turn results in adverse effects in patients’ clinical course.
Case presentation: This study represented data of consecutive patients with 5% to 10% BMPC at our center from 2004 to 2013. MM existed among patients, as expected. This series provides a quantitative approximation of MM prevalence in these cases.
Conclusion: The reported patients’ status demonstrates the limitations of the abovementioned cutoff criterion in myeloma diagnosis, and emphasizes the importance of employing further diagnostic procedures in patients with marginal amounts of BMPC and high clinical suspicion. It has been shown that supplementary examination is especially required for two subgroups of patients with certain clinical and laboratory characteristics. The detail of the cases and results are thoroughly explained in the paper. 
Full-Text [PDF 238 kb]   (2949 Downloads)    
Select article type: Case Report and Series | Subject: Supportive and Palliative Care
Received: 2018/05/4 | Accepted: 2018/07/15 | ePublished: 2018/08/7

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb